Leerink Partners Issues Positive Forecast for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price target boosted by Leerink Partners from $127.00 to $128.00 in a research report released on Wednesday,Benzinga reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

A number of other equities analysts have also recently issued reports on BSX. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Canaccord Genuity Group increased their target price on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a report on Wednesday. Robert W. Baird upped their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, UBS Group raised their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Price Performance

BSX stock opened at $97.30 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a PEG ratio of 2.32 and a beta of 0.61. The company’s fifty day simple moving average is $102.93 and its 200 day simple moving average is $102.05. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company posted $0.62 EPS. The business’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors have recently made changes to their positions in BSX. HM Payson & Co. boosted its position in Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock worth $694,000 after purchasing an additional 98 shares during the last quarter. Riverwater Partners LLC boosted its holdings in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management grew its position in Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares during the period. IVC Wealth Advisors LLC increased its holdings in Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after buying an additional 102 shares during the last quarter. Finally, Park Square Financial Group LLC boosted its stake in Boston Scientific by 5.2% in the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after acquiring an additional 103 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.